Is CLDX or CLLS more undervalued in 2026?

CirclFi compares Celldex Therapeutics, Inc. (CLDX) and Cellectis S.A. (CLLS) using 13 institutional-grade valuation models. CLDX has a Quality of Company score of 5.6/10 while CLLS scores 2.5/10.

Which is a better buy — CLDX or CLLS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CLDX and CLLS valuations compare?

CLDX at $31.70 and CLLS at $3.63 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CLDX vs CLLS Valuation Comparison 2026 — Intrinsic Value Analysis

CLDX

Biotechnology

Celldex Therapeutics, Inc.

Quality

5.6

out of 10

Value Trap

WARN

Price

$31.70

Last close

Models

12/13

Active

CLLS

Biotechnology

Cellectis S.A.

Quality

2.5

out of 10

Value Trap

SAFE

Price

$3.63

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	CLDX Fair Value	CLDX Upside	CLLS Fair Value	CLLS Upside
Bayesian DCF	Intrinsic	$9.79	-69.1%	$0.96	-73.5%
Earnings Power Value	Intrinsic	$1.05	-96.8%	$1.52	-61.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CLDX vs CLLS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CLDX vs CLLS — Which Stock Is More Undervalued?

CLDX scores higher with a 5.6/10 quality rating vs CLLS's 2.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Celldex Therapeutics, Inc. (CLDX) and Cellectis S.A. (CLLS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CLDX currently trades at $31.70 with a QOC of 5.6/10, while CLLS trades at $3.63 with a QOC of 2.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).